Effect of Closed Loop Pacemaker Treatment on Recurrent Vasovagal Syncope

Aarhus University Hospital Skejby

Status

Completed

Conditions

Vasovagal Syncope

Treatments

Device: Pacemaker, programmed as passive = VVI 30 beats per minute (bpm)

Device: Pacemaker treatment, pacemaker programmed as active = CLS

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00292825

skejbyH

Details and patient eligibility

About

The main purpose is to prevent syncope in patients with recurrent syncopal episodes caused by malignant vasovagal faints and bradycardia. Patients are treated by a special pacemaker (closed loop stimulation [CLS]) which can potentially identify an incipient attack and prevent syncope by pacing.

Full description

The treatment of patients with recurrent syncope of vasovagal origin, not precipitated by usual vasovagal factors, and not associated with structural heart disease, is unsolved. The limitations of the conducted 5 pacemaker studies are a significant placebo effect of pacemaker treatment, underpowering and lack of double blinding. The pacemaker intervention has been accelerated dual chamber pacing at the time of bradycardia, which may be too late. However, a pooling of all data indicate a beneficial effect of pacing.

Vasodilatation is an obligate element of all vasovagal syncopal episodes and in many also an early sign associated with the hyperkinetic empty left ventricle which triggers the reflex wave. The principle in closed loop stimulation (CLS) is a continuous surveillance of the impedance in the right ventricle which correlates highly with myocardial contractility. When contractility is increased significantly atrial pacing with prolonged AV delay is commenced. This principle has been used in chronotropic incompetent patients and in one small study of patients with vasovagal syncope with a positive outcome. The hypothesis is that the CLS will potentially identify an incipient vasovagal attack and be able to prevent the drop in cardiac output and bradycardia by early accelerated pacing.

Patients will be treated 12 months with active pacing (CLS) and then crossed over to 12 months with passive pacing (VVI, 30 bpm).

The study will be double blinded, only a technician will know the status of the pacemaker.

Enrollment

100 estimated patients

Sex

All

Ages

25+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

A clinical problem with vasovagal syncope which motivates considerations concerning pacemaker treatment.
A positive tilt-table test.
Exclusion of other causes for syncope by a complete diagnostic work-up allowing only minor cardiac abnormalities
Syncope for >= 2 years.
Number of syncopal episodes >= 3
At least 1 instance of syncope within the last 6 months.
A positive tilt-table test which reproduces the clinical syncope and is associated with a clearly abnormal haemodynamic response:
- Vasovagal Syncope International Study (VASIS) type 1 with bradycardia < 40 bpm, or
- VASIS type 2A, or
- VASIS type 2B
Stable clinical condition
Able to accept and follow the protocol and give written consent.

Exclusion criteria

Conventional indication for pacemaker (i.e. atrioventricular [AV] block)
Indication for cardiac resynchronisation therapy (i.e. left bundle branch block [LBBB])
Documented atrial fibrillation or flutter
Epilepsy
Congestive heart failure
History of myocardial infarction (MI) or angina pectoris
Serious chronic disease, life expectancy < 3 years.
Age < 25 years
Pregnant and lactating women
Participating in other investigation